Tata India Pharma & Healthcare Fund-Regular Plan-Growth

Open Ended Schemes(Equity Scheme - Sectoral/ Thematic)Very High RiskISIN INF277K016A9

NAV · 06-Jul-2026

₹32.9175

+6.04%

+8.01%

1Y (CAGR)

+7.71%

3Y (CAGR)

+21.55%

5Y (CAGR)

+13.33%

Since inception (CAGR)

+11.93%

NAV history

hover for values

Risk & SIP analytics

Q1 · TOP · 3Y in category

Volatility (3y)

13.37%

Downside dev (3y)

9.33%

Max drawdown (3y)

-17.0%

Sharpe (3y)

1.13

SIP XIRR (3y)

+13.11%

SIP XIRR (5y)

+16.88%

Calendar-year returns

2020 +64.4%2021 +19.1%2022 -8.0%2023 +36.6%2024 +40.4%2025 -4.9%

Fund facts

Fund managerRajat Srivastava

AUM₹13,869 Cr

TER · AMFI officialDirect 0.94% · Regular 2.25% (2026-06-30)

Launch date04-Dec-2015

Plan typeOpen Ended · Equity

Min lumpsumRs.5000 & in multiples of Re.1/- thereafter.

Lock-inNone

Volatility15.35

AMCTata Asset Management Limited

Objective · The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.

scheme documents ↗